Effect of chlorthalidone, amlodipine, and lisinopril on visit-to-visit variability of blood pressure: results from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. J Clin Hypertens (Greenwich) 2014 May;16(5):323-30
Date
04/18/2014Pubmed ID
24739073Pubmed Central ID
PMC4141643DOI
10.1111/jch.12290Scopus ID
2-s2.0-84900401881 (requires institutional sign-in at Scopus site) 47 CitationsAbstract
Few randomized trials have compared visit-to-visit variability (VVV) of systolic blood pressure (SBP) across drug classes. The authors compared VVV of SBP among 24,004 participants randomized to chlorthalidone, amlodipine, or lisinopril in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). VVV of SBP was calculated across 5 to 7 visits occurring 6 to 28 months following randomization. The standard deviation (SD) of SBP was 10.6 (SD=5.0), 10.5 (SD=4.9), and 12.2 (SD=5.8) for participants randomized to chlorthalidone, amlodipine, and lisinopril, respectively. After multivariable adjustment including mean SBP across visits and compared with participants randomized to chlorthalidone, participants randomized to amlodipine had a 0.36 (standard error [SE]: 0.07) lower SD of SBP and participants randomized to lisinopril had a 0.77 (SE=0.08) higher SD of SBP. Results were consistent using other VVV of SBP metrics. These data suggest chlorthalidone and amlodipine are associated with lower VVV of SBP than lisinopril.
Author List
Muntner P, Levitan EB, Lynch AI, Simpson LM, Whittle J, Davis BR, Kostis JB, Whelton PK, Oparil SAuthor
Jeffrey Whittle MD Professor in the Medicine department at Medical College of WisconsinMESH terms used to index this publication - Major topics in bold
Acute Coronary SyndromeAged
Amlodipine
Angiotensin-Converting Enzyme Inhibitors
Antihypertensive Agents
Blood Pressure
Blood Pressure Determination
Calcium Channel Blockers
Chlorthalidone
Dose-Response Relationship, Drug
Drug Therapy, Combination
Female
Humans
Hypertension
Hypolipidemic Agents
Lisinopril
Male
Office Visits
Prognosis
Risk Factors
Treatment Outcome
